Search
SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?
Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.
Jan 13
The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the...
Sep 10, 2024
.png){kind=logo}
